Riyuzo, Márcia Camegaçava [UNESP]Soares, Vitor Augusto [UNESP]2014-05-272014-05-271999-10-11Renal Failure, v. 21, n. 5, p. 469-475, 1999.0886-022Xhttp://hdl.handle.net/11449/65862The effect of ticlopidine on rats with adriamycin nephropathy was observed during 26 weeks. In the ticlopidine-treated nephrotic animals (TNG), proteinuria was less than in the untreated nephrotic animals (NG), but this difference was significant only at week 6 (TNG = 47.27 ± 16.52 versus NG = 100.08 ± 13.83 mg/24h, p < 0.01) and week 26 (TNG = 157.00 ± 28.73 versus NG = 217.00 ± 21.73 mg/24h, p< 0.01) after ADR injection. NG presented severe tubulointerstitial abnormalities with a tubulointerstitial lesion index of 3+. No difference in glomerular lesions was observed among the groups (NG median = 6%, TNG median = 4% and TCG median = 2%). The tubulointerstitial lesion index of TNG was less intense (median = 2+) but not different from those of the control groups (CG median = 1+; TCG median = 0+) nor NG (median = 3+). We concluded that the treatment with ticlopidine produced some partially beneficial effects but did not prevent the development of adriamycin-induced nephropathy.469-475engAdriamycin nephropathyAntiplatelet agentProgression of renal diseaseProteinuriaTiclopidinedoxorubicinticlopidineanimal cellanimal modelanimal tissuecontrolled studydrug efficacydrug mechanisminterstitial nephritisintravenous drug administrationkidney diseasemalenonhumanpriority journalproteinuriaratAnimalsAntibiotics, AntineoplasticDoxorubicinDrug Evaluation, PreclinicalKidneyMaleNephrosisPlatelet Aggregation InhibitorsRatsRats, WistarStatistics, NonparametricTime FactorsArtigo10.3109/08860229909045185WOS:000083048800002Acesso restrito2-s2.0-00328788191979519685789288